Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 nov. 2025 01h00 HE | Source: Pharming Group N.V.

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

Pharming Group reports Q3 2025 results with significant growth in revenue, profit, and cash flow driven by rare disease portfolio performance.
20 oct. 2025 02h00 HE | Source: Pharming Group N.V.

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10
01 oct. 2025 01h00 HE | Source: Pharming Group N.V.

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Pharming sNDA for leniolisib in children aged 4-11 years with APDS accepted and granted Priority Review by FDA.
05 avr. 2023 05h52 HE | Source: The Insight Partners

Artificial Pancreas Device System (APDS) Market Worth $3.58Bn, Globally, by 2028 at 20.28% CAGR | The Insight Partners

Pune, INDIA., April 05, 2023 (GLOBE NEWSWIRE) -- According to our new research study on “Artificial Pancreas Device System Market Forecast to 2028 – by Type and Geography,” the market is expected to...